Core Viewpoint - Ani Pharmaceuticals is expected to raise its 2025 guidance on May 9, 2025, due to the FDA approval of Purified Cortrophin Gel syringe and the marketing of two recently approved NDAs, INZIRQO [1] Group 1 - The FDA approval of Purified Cortrophin Gel syringe is a significant milestone for Ani Pharmaceuticals [1] - The marketing of two recently approved NDAs, INZIRQO, is anticipated to contribute positively to the company's performance [1] - The concept of "investigative investing" is being developed to identify undervalued stocks with significant price-moving information [1]